Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design
Biopharmaceuticals have developed rapidly in recent years due to the remarkable progress in gene recombination and cell culture technologies. Since the basic structure of biopharmaceuticals can be designed and modified, it is possible to control the duration of action and target specific tissues and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/5/1456 |
| _version_ | 1797600956770156544 |
|---|---|
| author | Takuo Ogihara Kenta Mizoi Akiko Ishii-Watabe |
| author_facet | Takuo Ogihara Kenta Mizoi Akiko Ishii-Watabe |
| author_sort | Takuo Ogihara |
| collection | DOAJ |
| description | Biopharmaceuticals have developed rapidly in recent years due to the remarkable progress in gene recombination and cell culture technologies. Since the basic structure of biopharmaceuticals can be designed and modified, it is possible to control the duration of action and target specific tissues and cells by kinetic modification. Amino acid sequence modifications, albumin fusion proteins, polyethylene glycol (PEG) modifications, and fatty acid modifications have been utilized to modify the duration of action control and targeting. This review first describes the position of biopharmaceuticals, and then the kinetics (absorption, distribution, metabolism, elimination, and pharmacokinetics) of classical biopharmaceuticals and methods of drug quantification. The kinetic innovations of biopharmaceuticals are outlined, including insulin analog, antibody-related drugs (monoclonal antibodies, Fab analogs, Fc analogs, Fab-PEG conjugated proteins, antibody-drug conjugates, etc.), blood coagulation factors, interferons, and other related drugs. We hope that this review will be of use to many researchers interested in pharmaceuticals derived from biological components, and that it aids in their knowledge of the latest developments in this field. |
| first_indexed | 2024-03-11T03:55:08Z |
| format | Article |
| id | doaj.art-cd44e3aebc254991a76d1087e74a0675 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T03:55:08Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-cd44e3aebc254991a76d1087e74a06752023-11-18T00:37:23ZengMDPI AGBiomedicines2227-90592023-05-01115145610.3390/biomedicines11051456Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular DesignTakuo Ogihara0Kenta Mizoi1Akiko Ishii-Watabe2Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki 370-0033, JapanFaculty of Pharmacy, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki 370-0033, JapanDivision of Biological Chemistry and Biologocals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki 210-9501, JapanBiopharmaceuticals have developed rapidly in recent years due to the remarkable progress in gene recombination and cell culture technologies. Since the basic structure of biopharmaceuticals can be designed and modified, it is possible to control the duration of action and target specific tissues and cells by kinetic modification. Amino acid sequence modifications, albumin fusion proteins, polyethylene glycol (PEG) modifications, and fatty acid modifications have been utilized to modify the duration of action control and targeting. This review first describes the position of biopharmaceuticals, and then the kinetics (absorption, distribution, metabolism, elimination, and pharmacokinetics) of classical biopharmaceuticals and methods of drug quantification. The kinetic innovations of biopharmaceuticals are outlined, including insulin analog, antibody-related drugs (monoclonal antibodies, Fab analogs, Fc analogs, Fab-PEG conjugated proteins, antibody-drug conjugates, etc.), blood coagulation factors, interferons, and other related drugs. We hope that this review will be of use to many researchers interested in pharmaceuticals derived from biological components, and that it aids in their knowledge of the latest developments in this field.https://www.mdpi.com/2227-9059/11/5/1456biopharmaceuticalspharmacokineticskinetic innovationspolyethylene glycol modificationantibody-related drugstargeting |
| spellingShingle | Takuo Ogihara Kenta Mizoi Akiko Ishii-Watabe Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design Biomedicines biopharmaceuticals pharmacokinetics kinetic innovations polyethylene glycol modification antibody-related drugs targeting |
| title | Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design |
| title_full | Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design |
| title_fullStr | Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design |
| title_full_unstemmed | Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design |
| title_short | Pharmacokinetics of Biopharmaceuticals: Their Critical Role in Molecular Design |
| title_sort | pharmacokinetics of biopharmaceuticals their critical role in molecular design |
| topic | biopharmaceuticals pharmacokinetics kinetic innovations polyethylene glycol modification antibody-related drugs targeting |
| url | https://www.mdpi.com/2227-9059/11/5/1456 |
| work_keys_str_mv | AT takuoogihara pharmacokineticsofbiopharmaceuticalstheircriticalroleinmoleculardesign AT kentamizoi pharmacokineticsofbiopharmaceuticalstheircriticalroleinmoleculardesign AT akikoishiiwatabe pharmacokineticsofbiopharmaceuticalstheircriticalroleinmoleculardesign |